SCHEMBL6726053

SCHEMBL6726053

Cc1ncccc1-c1noc(CO)c1-c1ccc(S(C)(=O)=O)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.41
PTGS1 P23219 2/20 0.41
BRD4 O60885 1/20 0.40
SYK P43405 1/20 0.38
PIK3CD O00329 2/20 0.37
PIK3CA P42336 2/20 0.37
PIK3CB P42338 2/20 0.37
PIK3CG P48736 2/20 0.37
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
EED O75530 1/20 0.36
SUZ12 Q15022 1/20 0.36
EZH2 Q15910 1/20 0.36
ALDH1A1 P00352 1/20 0.36
FEN1 P39748 4/20 0.35
GRM4 Q14833 1/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
ALOX5AP P20292 1/20 0.34
GLO1 Q04760 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6721775 0.91 PTGS2 (0.47) PTGS2PTGS1BRD4MKNK1MKNK2
SCHEMBL6725599 0.91 PTGS2 (0.41) PTGS2PTGS1SYKPIK3CDPIK3CA
SCHEMBL6734107 0.88 PTGS2 (0.40) PTGS2PTGS1BRD4MKNK1MKNK2
SCHEMBL6735027 0.87 PTGS2 (0.40) PTGS2PTGS1BRD4MKNK1MKNK2
SCHEMBL6723102 0.86 PTGS2 (0.46) PTGS2PTGS1BRD4SYKPIK3CD
SCHEMBL6723697 0.84 PTGS2 (0.46) PTGS2PTGS1BRD4PIK3CDPIK3CA
SCHEMBL6733277 0.84 PTGS2 (0.58) PTGS2PTGS1BRD4ALDH1A1PDE3A
SCHEMBL6723150 0.84 PTGS2 (0.45) PTGS2PTGS1BRD4ALDH1A1
SCHEMBL7109498 0.84 PTGS2 (0.40) PTGS2PTGS1BRD4MKNK1MKNK2
SCHEMBL6729415 0.83 BRD4 (0.44) PTGS2PTGS1BRD4PIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 PTGS2 5/4885PTGS1 4/4885BRD4 384/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 PTGS2 5/4885PTGS1 4/4885BRD4 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.